SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...

Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.

Credit: Thinkstock. The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

Researchers explored the incidence of erythrocytosis in the first 20 months of testosterone therapy among people receiving gender-affirming hormone therapy (GAHT). Specifically, they conducted a ...

Every year, millions of newborns—especially those born premature, underweight or sick—are at risk of neonatal hypoglycemia, a dangerous drop in blood sugar that can lead to seizures, brain injury and ...

Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks. Patients switching from placebo to rusfertide achieved rapid and ...

The use of testosterone as gender-affirming hormone therapy (GAHT) among transgender men is associated with a lower risk for erythrocytosis (abnormal blood cell elevation) than was previously reported ...